Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs investigator’s choice chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer after failure of first-line HER2-targeted therapy
CTR20233604Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Jan 2024; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233604.